EcoDrugPlus

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSDCDG00000032088
Gene Symbol: MAP3K13
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSDCDG00000019621
Gene Symbol: MAP3K5
3 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSDCDG00000016489
Gene Symbol: MAP3K8
3 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSDCDG00000014642
Gene Symbol: MAP3K9
3 Cross references
196 Possible Orthologues:

Motilin Receptor

Ensembl ID : ENSDCDG00000017318
Gene Symbol: MLNR
1 Cross references
172 Possible Orthologues:

Mucosal Pentraxin-Like

Ensembl ID : ENSDCDG00000004450
Gene Symbol: LOC114796014
2 Cross references
515 Possible Orthologues:

Muscarinic Acetylcholine Receptor M5-Like

Ensembl ID : ENSDCDG00000028208
Gene Symbol: LOC114798561
3 Cross references
195 Possible Orthologues:

Natriuretic Peptide Receptor 2

Ensembl ID : ENSDCDG00000016655
Gene Symbol: NPR2
2 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSDCDG00000021941
Gene Symbol: NPR3
3 Cross references
210 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSDCDG00000012926
Gene Symbol: LOC114785412
3 Cross references
195 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 1-Like

Ensembl ID : ENSDCDG00000003671
Gene Symbol: LOC114799220
3 Cross references
200 Possible Orthologues:

Neurogenic Locus Notch Homolog Protein 2-Like

Ensembl ID : ENSDCDG00000004626
Gene Symbol: LOC114793516
3 Cross references
194 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).